Company Overview and News
LifePoint Health Inc. (LPNT - Free Report) has high exposure to Hurricane Florence, with 30% of its beds in North and South Carolina, which is within the forecast path of the storm, as per analysts as pointed out in CNBC news. This makes the stock vulnerable to earnings miss in the third quarter. Other companies to face the wrath include Community Health Systems, Inc. (CYH - Free Report) , HCA Healthcare, Inc.
CYH LPNT CYHHZ ENPH OXY THC
Investors in Community Health Systems, Inc. (CYH - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Mar 15, 2019 $2.00 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other.
CYH HDS CYHHZ
WEST PALM BEACH, Fla, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Rennova Health, Inc. (OTC: RNVA), (OTC: RNVAW), (“Rennova” or the “Company”) a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers that acquired its second rural hospital in Tennessee on June 1, 2018, reports financial results for the three and six months ended June 30, 2018 and provides a business update.
CYH RNVAZ RNVA CYHHZ RNVAW
Community Health Systems, Inc. (CYH - Free Report) reported second-quarter loss of 1 cent per share, which was considerably better than the Zacks Consensus Estimate of a loss of 43 cents. In the year ago quarter, the company has incurred a loss of 31 cents per share. Earnings suffered from a decline in patient admissions.
CYH EA UHID FDC NVR CYHHZ UHS TRN UNH
(Reuters) - U.S. hospital operator HCA Healthcare Inc (HCA.N) raised its full-year earnings forecast as higher-than-expected patient admissions lifted second-quarter profit by 25 percent, sending its shares up 7 percent.
CYH CYHHZ THC
2018-07-23 bloomberg - 1
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
COTV CYH LPNT LFPI CYHHZ APO THC
Investors in Community Health Systems, Inc. (CYH - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 18, 2019 $5.00 Put had some of the highest implied volatility of all equity options today.
Hasbro – The toy maker earned 48 cents per share for the second quarter, well above the consensus estimate of 48 cents a share. Revenue also came in well above estimates. The performance came despite a drop in profit and revenue from a year ago due largely to the bankruptcy and liquidation of the Toys R Us chain.
CYH PM XKE SCGLF CALM LPNT SCGLY CYHHZ MDLZ GLE
HCA Healthcare, Inc. (HCA - Free Report) is scheduled to release second-quarter 2018 results on Jul 25. Last reported quarter, the company delivered a positive earnings surprise of nearly 11.2%. The company has likely witnessed an increase in revenues in the second quarter, continuing with the trend over the past few quarters. It is expected to have been driven by higher facility admissions and equivalent admissions, surgical growth and same facility emergency room growth.
ALGN CYH ALKS GLMD CYHHZ IQV
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET